US Patent 12018260 Tunable Reversir™ compounds
Patent 12018260 was granted and assigned to Alnylam Pharmaceuticals on June, 2024 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 12018260 Tunable Reversir™ compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
